Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial

Autor: Freyer, DR, Chen, L, Krailo, MD, Knight, K, Villaluna, D, Bliss, B, Pollock, BH, Ramdas, J, Lange, B, Van Hoff, D, VanSoelen, ML, Wiernikowski, J, Neuwelt, EA, Sung, L

Publikováno v: The Lancet. Oncology, vol 18, iss 1
Freyer, DR; Chen, L; Krailo, MD; Knight, K; Villaluna, D; Bliss, B; et al.(2017). Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 18(1), 63-74. doi: 10.1016/S1470-2045(16)30625-8. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/2bw5v78z

© 2017 Elsevier Ltd Background Sodium thiosulfate is an antioxidant shown in preclinical studies in animals to prevent cisplatin-induced hearing loss with timed administration after cisplatin without compromising the antitumour efficacy of cisplatin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::44cb515e2310bbfb7f1fe99506b25d73
https://escholarship.org/uc/item/2bw5v78z